Nasal Spray Reverses Brain Aging

Researchers at the Texas A&M University Naresh K. Vashisht College of Medicine have developed a non-invasive nasal spray designed to reverse signs of brain aging and reduce chronic inflammation. According to a report published on April 14, 2026, the therapy aims to treat a condition scientists call neuroinflammaging, the slow-burning inflammation in the brain’s memory center that contributes to cognitive decline and brain fog.

The study was led by Dr. Ashok Shetty, a university distinguished professor and associate director of the Institute for Regenerative Medicine, alongside senior research scientists Dr. Madhu Leelavathi Narayana, and Dr. Maheedhar Kodali. The team found that this inflammatory process, previously considered an inevitable part of aging, may be reversible.

Mechanism of the Nasal Therapy

The therapy utilizes a nasal spray to deliver microscopic delivery parcels known as intranasal extracellular vesicles directly into the brain. This delivery method allows the treatment to bypass more invasive procedures, such as brain surgery, to reach the memory center.

Once delivered, the therapy targets the brain’s cellular power plants, known as mitochondria. The research indicates that the spray can recharge these mitochondria while simultaneously reducing the chronic inflammation that characterizes the aging brain.

This inflammation is described as tiny fires that smolder within the brain, creating a persistent fog that hinders the ability to think, form new memories, or adapt to new environments. By extinguishing these inflammatory responses, the researchers observed a restoration of cognitive sharpness.

Study Results and Behavioral Recovery

The researchers reported that significant cognitive improvements occurred within weeks of treatment. Notably, these results persisted for months after the administration of only two doses.

In preclinical models, the treated subjects showed a restored ability to recognize familiar objects and adapt to changes in their environment. These behavioral changes serve as key indicators of a healthy, functioning memory center.

The study also noted a lack of variance in efficacy based on sex. The therapy proved equally effective in both male and female models, a finding the researchers highlighted as a significant detail given that many medical studies show varying results between sexes.

Future Applications and Clinical Path

While the current findings are based on preclinical models, the researchers believe the approach could be adapted for other neurological conditions. Potential future applications include helping stroke survivors rebuild lost functions or slowing the progression of Alzheimer’s disease.

The persistence of the results after a minimal dosage suggests a potential for long-term cognitive maintenance. The researchers aim for a future where individuals can remain mentally connected and sharp as they age, reducing the risks associated with age-related brain disorders.

Texas A&M has already filed a U.S. Patent for the therapy, indicating a move toward real-world clinical application and further testing.